首页> 外文期刊>Cellular and molecular biology >The combination therapy with esomeprazole and flupenthixol/melitracen in symptom improvement of erosive gastritis complicated with negative feelings compared with Esomeprazole alone
【24h】

The combination therapy with esomeprazole and flupenthixol/melitracen in symptom improvement of erosive gastritis complicated with negative feelings compared with Esomeprazole alone

机译:与eSomePrazole的症状改善eSomeprazole和Flupenthixol / eliTracen的联合治疗与eSomePrazole相比,腐蚀性胃炎的症状改善

获取原文
获取原文并翻译 | 示例
           

摘要

The purpose of this study was to evaluate the co-prescription efficacy of esomeprazole and flupenthixol/melitracen relative to that of solitary esomeprazole on erosive gastritis complicated with negative feelings. 140 erosive gastritis patients complicated with negative feelings enrolled in the present study. Seventy cases in the control group took esomeprazole, and 70 cases in the observation group received esomeprazole plus flupenthixol/Melitracen, both for 4 weeks. We gastroscopically checked the clinical symptoms, mucosal erosion, PGE2 and MDA levels in gastric mucosa, anxiety, depression, and recurrence before and after treatment in the groups. After treatment, the observation group had lower scores of clinical symptoms, mucosal erosions, Hamilton Depression Rating Scale (HAMD), and Hamilton Depression Rating Scale (HAMA) than the control group (p<0.05); as well, the observation group showed higher PGE2 and lower MDA levels than the control group (p<0.05); during six months of follow-up (100% follow-up rate), 16 and 34 recurrent cases occurred, respectively, in the observation and control groups (p<0.05). Co-prescription of esomeprazole and flupenthixol/melitracen improved the clinical symptoms and mucosal erosions, relieved negative feelings and reduced the recurrence rate. The efficacy of the co-prescription is higher than that of the solitary prescription.
机译:本研究的目的是评估埃索美拉唑和氟戊噻醇/美利曲辛联合用药与单独使用埃索美拉唑治疗伴有负面情绪的糜烂性胃炎的疗效。140例伴有负面情绪的糜烂性胃炎患者被纳入本研究。对照组70例服用埃索美拉唑,观察组70例服用埃索美拉唑加氟戊噻吨/美利曲辛,均持续4周。我们对两组患者治疗前后的临床症状、粘膜糜烂、胃粘膜PGE2和MDA水平、焦虑、抑郁和复发进行了胃镜检查。治疗后,观察组的临床症状、粘膜糜烂、汉密尔顿抑郁量表(HAMD)、汉密尔顿抑郁量表(HAMA)评分均低于对照组(p<0.05);观察组PGE2水平高于对照组,MDA水平低于对照组(p<0.05);随访6个月(100%随访率),观察组和对照组分别有16例和34例复发(p<0.05)。埃索美拉唑和氟戊噻醇/美利曲辛联合用药改善了临床症状和粘膜糜烂,缓解了负面情绪,降低了复发率。联合处方的疗效高于单独处方。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号